bit.bio Stock

bit.bio represents the two fields coding and biology that determine the identity of every human cell.

Sign up today and learn more about bit.bio Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About bit.bio Stock

bit.bio is an award-winning human synthetic biology enterprise. Our mission is coding cells for health. To do so, we apply the principles of computation to biology. Our current focus is to develop a scalable technology platform capable of producing consistent batches of every human cell. This has the potential to unlock a new generation of medicine: it will enable research and drug discovery to move on from inappropriate models and work with the cells that actually are affected by human disease. A scalable platform of consistent cells will also be the basis for a new generation of cell and tissue therapies. To achieve our goals, we have assembled a team of pioneers in stem cells, cellular reprogramming, mathematical modelling, and cell therapy. Collaboration is at the heart of bit.bio. We are empirical, highly ambitious and driven by a common purpose.

Funding History

March 2019$3.8M
February 2020$412K
February 2020$41.1M
September 2021$3.5M
September 2021$137M

Management

Founder

Mark Kotter

CFO & COO

Florian Schuster

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo